BR112013003766B1 - Processo para a produção de uma vacina à base de vírus da gripe e uso de um amniócito humano permanente - Google Patents

Processo para a produção de uma vacina à base de vírus da gripe e uso de um amniócito humano permanente Download PDF

Info

Publication number
BR112013003766B1
BR112013003766B1 BR112013003766-0A BR112013003766A BR112013003766B1 BR 112013003766 B1 BR112013003766 B1 BR 112013003766B1 BR 112013003766 A BR112013003766 A BR 112013003766A BR 112013003766 B1 BR112013003766 B1 BR 112013003766B1
Authority
BR
Brazil
Prior art keywords
cells
influenza virus
medium
cell
infection
Prior art date
Application number
BR112013003766-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013003766A2 (pt
Inventor
Gudrun Schiedner
Udo Reichl
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Publication of BR112013003766A2 publication Critical patent/BR112013003766A2/pt
Publication of BR112013003766B1 publication Critical patent/BR112013003766B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112013003766-0A 2010-08-16 2011-08-16 Processo para a produção de uma vacina à base de vírus da gripe e uso de um amniócito humano permanente BR112013003766B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102010037008.8 2010-08-16
DE102010037008 2010-08-16
DE102011050353 2011-05-13
DE102011050353.6 2011-05-13
PCT/DE2011/075194 WO2012041311A1 (de) 2010-08-16 2011-08-16 Permanente humane amniozyten zelllinie zur herstellung von influenzaviren

Publications (2)

Publication Number Publication Date
BR112013003766A2 BR112013003766A2 (pt) 2016-05-31
BR112013003766B1 true BR112013003766B1 (pt) 2021-08-24

Family

ID=44936126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003766-0A BR112013003766B1 (pt) 2010-08-16 2011-08-16 Processo para a produção de uma vacina à base de vírus da gripe e uso de um amniócito humano permanente

Country Status (19)

Country Link
US (1) US20130344569A1 (enExample)
EP (1) EP2606128B1 (enExample)
JP (1) JP5928843B2 (enExample)
KR (1) KR101780257B1 (enExample)
CN (1) CN103168100B (enExample)
AU (1) AU2011307655B2 (enExample)
BR (1) BR112013003766B1 (enExample)
CA (1) CA2808453C (enExample)
DE (1) DE112011102737A5 (enExample)
DK (1) DK2606128T3 (enExample)
ES (1) ES2524894T3 (enExample)
IL (1) IL224728A (enExample)
MX (1) MX337687B (enExample)
PL (1) PL2606128T3 (enExample)
PT (1) PT2606128E (enExample)
RU (1) RU2565546C2 (enExample)
SG (1) SG187863A1 (enExample)
TW (1) TW201211257A (enExample)
WO (1) WO2012041311A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
CN121343924A (zh) * 2024-07-15 2026-01-16 干细胞转化研究中心有限公司 极早期干细胞在流感病毒制备、检测和药物筛选中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20050170463A1 (en) 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ES2526170T3 (es) * 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
ES2402061T3 (es) * 2005-10-17 2013-04-26 Medimmune, Llc Método de aumento de la replicación del virus influenza
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
AU2007347716B2 (en) * 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same

Also Published As

Publication number Publication date
WO2012041311A1 (de) 2012-04-05
AU2011307655B2 (en) 2015-12-17
MX2013001772A (es) 2013-06-03
EP2606128B1 (de) 2014-09-10
ES2524894T3 (es) 2014-12-15
CA2808453C (en) 2020-05-05
CN103168100B (zh) 2016-04-13
IL224728A (en) 2016-05-31
CA2808453A1 (en) 2012-04-05
KR101780257B1 (ko) 2017-09-21
TW201211257A (en) 2012-03-16
PL2606128T3 (pl) 2015-02-27
SG187863A1 (en) 2013-03-28
EP2606128A1 (de) 2013-06-26
RU2565546C2 (ru) 2015-10-20
RU2013110786A (ru) 2014-09-27
KR20130097191A (ko) 2013-09-02
JP5928843B2 (ja) 2016-06-01
JP2013537543A (ja) 2013-10-03
BR112013003766A2 (pt) 2016-05-31
CN103168100A (zh) 2013-06-19
AU2011307655A1 (en) 2013-03-21
US20130344569A1 (en) 2013-12-26
DE112011102737A5 (de) 2013-06-06
DK2606128T3 (en) 2014-12-01
MX337687B (es) 2016-03-15
PT2606128E (pt) 2014-12-09

Similar Documents

Publication Publication Date Title
AU2006234304B2 (en) Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
US20050118698A1 (en) Multiplication of viruses in a cell culture
CN101193655A (zh) 抗大流行性流感病毒株的疫苗
JP5928843B2 (ja) インフルエンザウイルスを製造するための永久ヒト羊膜細胞株
CN108888761B (zh) 表达h7n9亚型禽流感病毒血凝素蛋白的重组杆状病毒灭活疫苗及其制备方法与应用
CN119372158B (zh) 共同表达h9亚型aiv ha基因、ibv s基因和ibdv vp2基因的重组hvt及其应用
CN106215184A (zh) 一种h7亚型重组禽流感病毒活载体疫苗毒种的制备方法
RU2811791C1 (ru) Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
CN119351357B (zh) 一种表达h9亚型aiv ha基因和ibv s基因的重组火鸡疱疹病毒株及其应用
US20240285748A1 (en) Veterinary viral vector
AU2020103705A4 (en) Heat-resistant h1n1 subtype influenza virus mutant strain, preparation method and application thereof
KR102568329B1 (ko) 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신
Nurpeisova et al. Determining optimal conditions for growing recombinant vectors to be used in developing a bovine tuberculosis vaccine
Bayer Novel approaches to an RSV vaccine
Schwarzer et al. METABOLISM OF AVIAN DESIGNER CELLS DURING INFLUENZA AND MVA PRODUCTION
WO2009132195A1 (en) Immortal avian cell line and methods of use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/08/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25G Requested change of headquarter approved

Owner name: CEVEC PHARMACEUTICALS GMBH (DE)